Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma.

Law PT, Ching AK, Chan AW, Wong QW, Wong CK, To KF, Wong N.

Carcinogenesis. 2012 Jun;33(6):1134-41. doi: 10.1093/carcin/bgs130. Epub 2012 Mar 19.

PMID:
22431718
2.

MicroRNA-145 suppresses hepatocellular carcinoma by targeting IRS1 and its downstream Akt signaling.

Wang Y, Hu C, Cheng J, Chen B, Ke Q, Lv Z, Wu J, Zhou Y.

Biochem Biophys Res Commun. 2014 Apr 18;446(4):1255-60. doi: 10.1016/j.bbrc.2014.03.107. Epub 2014 Mar 29.

PMID:
24690171
3.

MiR-214 inhibits cell growth in hepatocellular carcinoma through suppression of β-catenin.

Wang X, Chen J, Li F, Lin Y, Zhang X, Lv Z, Jiang J.

Biochem Biophys Res Commun. 2012 Nov 30;428(4):525-31. doi: 10.1016/j.bbrc.2012.10.039. Epub 2012 Oct 12.

PMID:
23068095
4.

MiR-222 overexpression confers cell migratory advantages in hepatocellular carcinoma through enhancing AKT signaling.

Wong QW, Ching AK, Chan AW, Choy KW, To KF, Lai PB, Wong N.

Clin Cancer Res. 2010 Feb 1;16(3):867-75. doi: 10.1158/1078-0432.CCR-09-1840. Epub 2010 Jan 26.

5.

MicroRNA-99a inhibits hepatocellular carcinoma growth and correlates with prognosis of patients with hepatocellular carcinoma.

Li D, Liu X, Lin L, Hou J, Li N, Wang C, Wang P, Zhang Q, Zhang P, Zhou W, Wang Z, Ding G, Zhuang SM, Zheng L, Tao W, Cao X.

J Biol Chem. 2011 Oct 21;286(42):36677-85. doi: 10.1074/jbc.M111.270561. Epub 2011 Aug 30.

6.

miR-615-5p is restrictedly expressed in cirrhotic and cancerous liver tissues and its overexpression alleviates the tumorigenic effects in hepatocellular carcinoma.

El Tayebi HM, Hosny KA, Esmat G, Breuhahn K, Abdelaziz AI.

FEBS Lett. 2012 Sep 21;586(19):3309-16. doi: 10.1016/j.febslet.2012.06.054. Epub 2012 Jul 20.

7.

MicroRNA-503 inhibits the G1/S transition by downregulating cyclin D3 and E2F3 in hepatocellular carcinoma.

Xiao F, Zhang W, Chen L, Chen F, Xie H, Xing C, Yu X, Ding S, Chen K, Guo H, Cheng J, Zheng S, Zhou L.

J Transl Med. 2013 Aug 22;11:195. doi: 10.1186/1479-5876-11-195.

8.

MicroRNA-214 downregulation contributes to tumor angiogenesis by inducing secretion of the hepatoma-derived growth factor in human hepatoma.

Shih TC, Tien YJ, Wen CJ, Yeh TS, Yu MC, Huang CH, Lee YS, Yen TC, Hsieh SY.

J Hepatol. 2012 Sep;57(3):584-91. doi: 10.1016/j.jhep.2012.04.031. Epub 2012 May 18.

PMID:
22613005
9.

Underexpressed microRNA-199b-5p targets hypoxia-inducible factor-1α in hepatocellular carcinoma and predicts prognosis of hepatocellular carcinoma patients.

Wang C, Song B, Song W, Liu J, Sun A, Wu D, Yu H, Lian J, Chen L, Han J.

J Gastroenterol Hepatol. 2011 Nov;26(11):1630-7. doi: 10.1111/j.1440-1746.2011.06758.x.

PMID:
21557766
10.

Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma.

Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA, Zhuang H.

Cancer. 2012 May 1;118(9):2431-42. doi: 10.1002/cncr.26566. Epub 2011 Oct 11.

11.

A novel GSK-3 beta-C/EBP alpha-miR-122-insulin-like growth factor 1 receptor regulatory circuitry in human hepatocellular carcinoma.

Zeng C, Wang R, Li D, Lin XJ, Wei QK, Yuan Y, Wang Q, Chen W, Zhuang SM.

Hepatology. 2010 Nov;52(5):1702-12. doi: 10.1002/hep.23875.

PMID:
21038412
12.
13.

MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo.

He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH, Lin JS.

Oncogene. 2012 Jul 12;31(28):3357-69. doi: 10.1038/onc.2011.500. Epub 2011 Nov 7.

PMID:
22056881
14.

Re-expression of transcription factor ATF5 in hepatocellular carcinoma induces G2-M arrest.

Gho JW, Ip WK, Chan KY, Law PT, Lai PB, Wong N.

Cancer Res. 2008 Aug 15;68(16):6743-51. doi: 10.1158/0008-5472.CAN-07-6469.

15.

Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma.

Hung TM, Ho CM, Liu YC, Lee JL, Liao YR, Wu YM, Ho MC, Chen CH, Lai HS, Lee PH.

PLoS One. 2014 Feb 20;9(2):e89446. doi: 10.1371/journal.pone.0089446. eCollection 2014.

16.

MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3.

Zhao N, Wang R, Zhou L, Zhu Y, Gong J, Zhuang SM.

Mol Cancer. 2014 Feb 24;13:35. doi: 10.1186/1476-4598-13-35.

17.

MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/β-catenin pathway.

Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, Wu F.

Liver Int. 2012 May;32(5):752-60. doi: 10.1111/j.1478-3231.2011.02750.x. Epub 2012 Jan 26.

PMID:
22276989
18.

MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells.

Liu WH, Yeh SH, Lu CC, Yu SL, Chen HY, Lin CY, Chen DS, Chen PJ.

Gastroenterology. 2009 Feb;136(2):683-93. doi: 10.1053/j.gastro.2008.10.029. Epub 2008 Nov 1.

PMID:
19027010
19.

MiR-138 induces cell cycle arrest by targeting cyclin D3 in hepatocellular carcinoma.

Wang W, Zhao LJ, Tan YX, Ren H, Qi ZT.

Carcinogenesis. 2012 May;33(5):1113-20. doi: 10.1093/carcin/bgs113. Epub 2012 Feb 23.

20.

MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.

Chen Z, Ma T, Huang C, Zhang L, Lv X, Xu T, Hu T, Li J.

Cell Signal. 2013 Dec;25(12):2693-701. doi: 10.1016/j.cellsig.2013.08.032. Epub 2013 Sep 7.

PMID:
24018051

Supplemental Content

Support Center